222 related articles for article (PubMed ID: 18703645)
41. Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.
Dang Q; Kasibhatla SR; Jiang T; Fan K; Liu Y; Taplin F; Schulz W; Cashion DK; Reddy KR; van Poelje PD; Fujitaki JM; Potter SC; Erion MD
J Med Chem; 2008 Jul; 51(14):4331-9. PubMed ID: 18570362
[TBL] [Abstract][Full Text] [Related]
42. Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.
Wang H; Wang Z; Wang S; Li M; Nan L; Rhie JK; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):255-60. PubMed ID: 15868148
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats.
Zhu J; Hu Y; Ho MK; Wong YH
Xenobiotica; 2012 Nov; 42(11):1138-50. PubMed ID: 22642804
[TBL] [Abstract][Full Text] [Related]
44. Factors limiting the extent of absolute bioavailability of pradefovir in rat.
Xiao Q; Yang W; Wang D; Chen L; Yuan L; Ding Y; Yang J
Xenobiotica; 2016 Oct; 46(10):913-21. PubMed ID: 26846680
[TBL] [Abstract][Full Text] [Related]
45. Metabolism distribution and excretion of a matrix metalloproteinase-13 inhibitor, 4-[4-(4-fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439), in rats and dogs: assessment of the metabolic profile of CP-544439 in plasma and urine of humans.
Dalvie D; Cosker T; Boyden T; Zhou S; Schroeder C; Potchoiba MJ
Drug Metab Dispos; 2008 Sep; 36(9):1869-83. PubMed ID: 18566038
[TBL] [Abstract][Full Text] [Related]
46. Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer.
Beconi M; Mao A; Creighton M; Hop CE; Chiu SH; Eydelloth R; Franklin R; Tang F; Yu N; Vincent S
Xenobiotica; 2003 Jul; 33(7):767-87. PubMed ID: 12893525
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of SB-247083, a potent and selective endothelin(A) receptor antagonist, in the rat, dog, and monkey.
Ward KW; Azzarano LM; Morgan JA; Gould MJ; Perng CY; Souder PR; Lundberg D; Smith BR
Biopharm Drug Dispos; 2002 Nov; 23(8):339-49. PubMed ID: 12415574
[TBL] [Abstract][Full Text] [Related]
48. First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism.
Zimmerman CL; Wen Y; Remmel RP
Drug Metab Dispos; 2000 Jun; 28(6):672-9. PubMed ID: 10820140
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
[TBL] [Abstract][Full Text] [Related]
50. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
51. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
52. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.
Mamidi RN; Mullangi R; Kota J; Bhamidipati R; Khan AA; Katneni K; Datla S; Singh SK; Rao KY; Rao CS; Srinivas NR; Rajagopalan R
Biopharm Drug Dispos; 2002 Oct; 23(7):273-82. PubMed ID: 12355578
[TBL] [Abstract][Full Text] [Related]
54. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
[TBL] [Abstract][Full Text] [Related]
55. Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist.
Nakamura A; Yamada T; Asaki T
Bioorg Med Chem; 2007 Dec; 15(24):7720-5. PubMed ID: 17881233
[TBL] [Abstract][Full Text] [Related]
56. Enzymatic stability of 2'-ethylcarbonate-linked paclitaxel in serum and conversion to paclitaxel by rabbit liver carboxylesterase for use in prodrug/enzyme therapy.
Tanino T; Nawa A; Miki Y; Iwaki M
Biopharm Drug Dispos; 2008 Jul; 29(5):259-69. PubMed ID: 18496885
[TBL] [Abstract][Full Text] [Related]
57. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs.
Prueksaritanont T; Gorham LM; Yeh KC
J Pharm Sci; 1997 Dec; 86(12):1345-51. PubMed ID: 9423143
[TBL] [Abstract][Full Text] [Related]
58. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
59. First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme.
Wen Y; Remmel RP; Zimmerman CL
Drug Metab Dispos; 1999 Jan; 27(1):113-21. PubMed ID: 9884319
[TBL] [Abstract][Full Text] [Related]
60. Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans.
Zhu M; Whigan DB; Chang SY; Dockens RC
Drug Metab Dispos; 2008 Jan; 36(1):24-35. PubMed ID: 17908924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
